晚期非小细胞肺癌患者铂类药物敏感性与ERCC1和BAG-1基因多态性的关联性研究

目的探讨晚期非小细胞肺癌患者铂类药物敏感性与ERCC1和BAG-1基因多态性间的关联性。方法随机选取接受铂类药物化疗的NSCLC患者100例，采用PCR—RFLP法和Logistic回归模型检测和分析患者ERCC1和BAG～1位点多态性及其与铂类药物敏感性的关联性。结果ERCC1位点基因型频率分为CC、TF和CT型分别占61．0％、7．0％和32．0％；CC型患者对铂类药物敏感性是T基因携带者的2．523倍，达到显著（P〈0．05）；BAG-1位点基因型频率CC、TT和CT型分别占77．0％、2．0％和21．0％，CC型患者对铂类药物敏感性是T基因携带者的2．738倍，达到显著（P〈0．05）。结论ERCC1和BAG—1基因多态性可能与NSCLC患者对铂类药物敏感性存在关联性，CC基因型可能对铂类药物较为敏感。

The association between the susceptibility to platinum drugs and the ge- netic polymorphisms of ERCC 1 and BAG-1 in patients with advanced non-small cell lung cancer

Objective To discuss the association between the susceptibility to platinum drugs and the genetic polymor- phisms of ERCC 1 and BAG-1 in patients with advanced non-small cell lung cancer. Methods All 100 NSCLC pa- tients who had received platinum drugs chemotherapy were selected randomly. The polymerasc chain reaction-restric- tion fragment length polymorphism and the Logistic regression model were used to detect and analyze the genetic polymorphisms of ERCC 1 and BAG-1 and the association between the susceptibility to platinum drugs and the genetic polymorphisms of ERCC 1 and BAG-1 in the patients with advanced non-small cell lung cancer. Results The ERCC1 site genotype frequency of CC, TY and CT was 61.0%, 7.0% and 32.0%. The susceptibility to platinum drugs of the patients with ERCC1 site CC genotype was 2.523 times as the gene T carriers, with the significantly relevance （P 〈 0.05）. The BAG-1 site genotype frequency of CC, 3~F and CT was 77.0%, 2.0% and 21.0%. The susceptibility to platinum drugs of the patients with BAG-1 site CC genotype was 2.738 times as the gene T carriers, with the signifi- cantly relevance （P 〈 0.05 ）. Conclusion The gene single nucleotide polymorphisms of ERCC 1 and BAG-1 may have relevance to the susceptibility to platinum drugs of the NSCLC patients. The CC genotype may be more sensitive to platinum drugs.